Nevertheless, unlike squamous cell carcinoma, in which the inhibition of AR of CAFs could be beneficial, low levels or loss of AR in the stromal cells of prostate cancer are associated with poorer clinical outcomes [17–22]. The gene discussed is AR; the disease is prostate cancer.